MYOMO, INC. (MYO) Q3 2025 10-Q Quarterly Report

Filed: Nov 10, 2025Period ending Sep 30, 2025
Health Care
Orthopedic, Prosthetic & Surgical Appliances & SuppliesSEC EDGAR

MYOMO, INC. (MYO) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 10, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

MYOMO, INC. Q3 2025 10-Q Analysis

Risk Factors

  • New direct-to-consumer advertising risk triggered by social media algorithm change in Q1 2025 causing higher cost per pipeline add and lower lead generation
  • Material update to capital risk from $17.5M loan facility entered Nov 2025, replacing prior $7M facility, with covenants restricting operations and financial flexibility
  • Regulatory risk from ongoing Medicare pre-payment audits impacting 43 claims, with 8 claims currently under appeal as of 10-Q filing date
  • Near-term market risk from Medicare Advantage plans reducing MyoPro authorizations, lowering revenues from 24% to 18% of total quarterly revenue YoY
  • Financial liquidity risk: $12.6M cash Sept 30, 2025, with recent borrowings of $3M term loan and $1M line of credit, expected to fund operations for next 12 months

MYOMO, INC. Q3 2025 Quarterly Financials
XBRL

Revenue

$10M

+9.6% YoY +4.5% QoQ

Net Income

-$4M

-279.0% YoY +20.9% QoQ

Gross Margin

63.8%

-1159bp YoY +114bp QoQ

Operating Margin

-34.9%

-2446bp YoY +1270bp QoQ

Net Margin

-36.3%

-2580bp YoY +1169bp QoQ

ROE

-25.0%

Total Assets

$34M

EPS (Diluted)

$-0.08

-166.7% YoY +33.3% QoQ

Operating Cash Flow

-$2M

-22.4% YoY +79.4% QoQ

Source: XBRL data from MYOMO, INC. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.

Get deeper insights on MYOMO, INC.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.